Learn the typical dosage for AOD 9604 used in studies, including 5mg vial reconstitution, injection timing, and how men and women compare in research.
There is no FDA-approved dosage for AOD 9604 because the peptide is not an approved drug for human use in the United States. Published human trials delivered AOD 9604 orally at milligram-level doses once daily under medical supervision, while research-use protocols described online commonly list 250 mcg to 500 mcg injected under the skin once per day. Those figures are reference points for research discussions, not a medical recommendation.
Why No Official AOD 9604 Dose Exists
AOD 9604 is a synthetic fragment of human growth hormone, built from the 176-191 region of the hGH molecule. Researchers studied it because that fragment appears to influence fat metabolism without the blood sugar effects associated with full growth hormone.
The key point for anyone searching a dose is simple: there is no universally accepted human dosage for AOD 9604. The peptide never completed the regulatory process required to become a prescription medication, so there is no product label, no standard pharmacy strength, and no dosing guideline published by a medical authority.
Everything below describes what appears in clinical literature and research-use communities. It is not a prescription, and it is not medical advice.
Typical AOD 9604 Dosage Ranges in Research
Because no standard exists, protocols vary widely. The ranges below reflect what is most often described, and they should be read as a spectrum rather than a schedule.
| Research context | Typical daily range | Frequency | Notes |
|---|---|---|---|
| Conservative starting range | 100-250 mcg | Once daily | Often used to gauge tolerance |
| Most commonly cited protocol | 250-500 mcg | Once daily | Widest range reported online |
| Higher research range | 500 mcg-1 mg | Once or split twice daily | Reported less often |
| Human clinical trials (oral) | Milligram-level doses | Once daily | Supervised, oral formulation only |
Notice the wide gap between injected research amounts measured in micrograms and trial amounts measured in milligrams. Route of administration and formulation explain most of that difference, and it is one reason online numbers can be confusing.
Reconstituting a 5 mg Vial: The Dosing Math
Most AOD 9604 sold for research arrives as a 5 mg lyophilized powder that has to be reconstituted with bacteriostatic water. The volume you add sets the concentration, and the concentration sets how much liquid equals one dose.
Working out the aod-9604 5mg dosage is straightforward arithmetic once the concentration is known.
| Bacteriostatic water added | Concentration | Volume for 250 mcg | Volume for 500 mcg |
|---|---|---|---|
| 1 mL | 5,000 mcg/mL | 0.05 mL (5 units on a U-100 syringe) | 0.10 mL (10 units) |
| 2 mL | 2,500 mcg/mL | 0.10 mL (10 units) | 0.20 mL (20 units) |
| 5 mL | 1,000 mcg/mL | 0.25 mL (25 units) | 0.50 mL (50 units) |
Adding more bacteriostatic water does not change the total amount of peptide in the vial, and it does not change the dose. It only changes how much liquid you draw into the syringe.
Some people look for an aod 9604 dosage calculator for weight loss pdf that converts body weight into micrograms. No validated weight-based formula exists for this peptide, so those calculators are approximations at best.
AOD 9604 Dosage Protocol: Timing and Frequency
Two timing patterns show up most often in research-use discussions.
- Once daily: a single subcutaneous injection in the morning, often on an empty stomach or before fasted cardio.
- Split dosing: half the daily amount in the morning and half in the early afternoon, used by people who report short-lived effects.
AOD 9604 has a short half-life, which is why some protocols favor splitting the dose. Most descriptions suggest 8-12 week cycles followed by a break, though that convention comes from community practice rather than controlled trials.
Injection site rotation matters too. Repeatedly using the same spot raises the chance of irritation, redness, and small lumps under the skin.
What the Human Trials Actually Used
The clinical research on AOD 9604 did not use the small subcutaneous doses popular in research circles. Trials in overweight and obese adults used an oral formulation at milligram-level doses taken once daily, and the results were modest.
Published studies reported some reduction in body fat and changes in certain metabolic markers, but the effects were generally small and not consistent enough to support regulatory approval. Human clinical trials of AOD 9604 used oral milligram-level doses, not the microgram injections described in community protocols.
That history is why comparing trial data to research-use dosing is difficult. The delivery method, the dose, and the oversight are all different.
Men, Women, and First-Time Researchers
No published data shows a meaningful difference in how men and women respond to AOD 9604, so a separate aod 9604 dosage for men is not supported by evidence. The same is true for aod 9604 dosage for women; most protocols apply the same microgram range to both.
Body weight may influence how a fixed dose feels, but there is no validated weight-based formula for this peptide. Anyone new to the compound should treat an aod 9604 peptide dosage for beginners as a conservative starting point, not a target to reach quickly.
Experience level changes judgment more than it changes biology. Starting low and holding the same dose long enough to observe effects is more useful than escalating quickly.
Safety, Side Effects, and Legal Status
AOD 9604 is not FDA-approved for human use in the United States. It is sold as a research chemical, which means it is not manufactured under pharmaceutical quality standards and its purity is not guaranteed.
- Side effects reported in trials: injection site reactions, headache, nausea, and mild gastrointestinal discomfort.
- Unknown long-term risks: effects on hormone balance, pregnancy safety, and interactions with other medications.
- Practical risks: incorrect reconstitution math, contaminated vials, and unverified product purity.
Talk with a licensed healthcare professional before using any research peptide. Blood work, medical history, and prescription interactions are things only a clinician can evaluate properly.
The Bottom Line on Dosing AOD 9604
There is no official dosage for AOD 9604, and no human dose has been approved by any regulatory agency. The most frequently cited research range is 250 mcg to 500 mcg per day by subcutaneous injection, while clinical trials used oral doses measured in milligrams.
Reconstitution math, timing, and cycle length all vary by protocol rather than by evidence. Anyone relying on community numbers should understand that they reflect informal practice, not proven medicine.
Frequently Asked Questions
What is the typical dosage for AOD 9604?
No official human dosage exists. Published clinical trials used oral AOD 9604 in milligram-level doses once daily under supervision, while research-use protocols commonly describe 250 mcg to 500 mcg injected subcutaneously per day. Those community numbers are not backed by an approved label or medical guideline.
How do I reconstitute a 5 mg AOD 9604 vial for dosing?
Adding 1 mL of bacteriostatic water to a 5 mg vial creates a concentration of 5,000 mcg/mL, so 0.05 mL equals 250 mcg and 0.10 mL equals 500 mcg. Adding 2 mL halves the concentration and doubles the volume needed per dose. Always use a U-100 insulin syringe and check the math twice.
Is AOD 9604 FDA-approved and legal to use?
AOD 9604 is not FDA-approved for human use in the United States. It is sold as a research chemical, and it is not legal to market or use it as a prescription drug. Anyone considering it should speak with a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.